DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

Not Applicable

Recruiting

Conditions: Cancer Predisposition Syndrome
Predisposition, Genetic

Interventions: Other: GRAIL Galleri Test

First Posted Date: 2024-06-10

Last Posted Date: 2024-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1000

Registration Number: NCT06450171

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Stage IV Breast Cancer
Breast Cancer Metastatic
Breast Cancer Female
Breast Cancer
Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Nab-Paclitaxel
Drug: Paclitaxel
Drug: Docetaxel
Drug: Phesgo
Drug: T-DM1
Drug: Pertuzumab
Drug: Trastuzumab Deruxtecan
Drug: Trastuzumab Subcutaneous Subcutaneous
Drug: Tucatinib
Drug: Trastuzumab

First Posted Date: 2024-06-03

Last Posted Date: 2024-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 72

Registration Number: NCT06439693

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab

Phase 2

Recruiting

Conditions: Endometrial Cancer
Recurrent Endometrial Cancer
TP53

Interventions: Drug: Abemaciclib
Drug: Pembrolizumab
Drug: Letrozole

First Posted Date: 2024-04-15

Last Posted Date: 2024-10-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 76

Registration Number: NCT06366347

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

PediCARE Health Equity Intervention in High-Risk Neuroblastoma

Not Applicable

Withdrawn

Conditions: Poverty
High-risk Neuroblastoma
Neuroblastoma
Disparities
Financial Stress
Pediatric Cancer

Interventions: Behavioral: PediCARE Intervention

First Posted Date: 2024-03-28

Last Posted Date: 2024-08-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT06335745

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

Not Applicable

Recruiting

Conditions: Breast Cancer
Breast Cancer Female

Interventions: Behavioral: Exercise Training Program

First Posted Date: 2024-03-21

Last Posted Date: 2024-12-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT06322888

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Platinum-resistant Ovarian Cancer
Ovarian Carcinoma
Ovarian Carcinoma, Recurrent
Recurrent Ovary Cancer
Ovarian Cancer

Interventions: Biological: Cytokine-Induced Memory-like Natural Killer Cells
Drug: Interleukin 2

First Posted Date: 2024-03-20

Last Posted Date: 2024-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT06321484

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Early Phase 1

Not yet recruiting

Conditions: Renal Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Chromophobe Renal Cell Carcinoma

Interventions: Biological: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Drug: Interleukin-2 (IL-2)

First Posted Date: 2024-03-19

Last Posted Date: 2024-07-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT06318871

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer
Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Carboplatin
Drug: 177Lu-PSMA-617

First Posted Date: 2024-03-12

Last Posted Date: 2024-05-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT06303713

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Not Applicable

Recruiting

Conditions: Advanced Melanoma
Skin Cancer
Melanoma (Skin)

Interventions: Behavioral: Exercise Program
Behavioral: Diet Program

First Posted Date: 2024-03-07

Last Posted Date: 2024-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06298734

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

PediRISE Feasibility

Not Applicable

Recruiting

Conditions: Pediatric Cancer
Financial Stress
Financial Hardship
Disparities

Interventions: Behavioral: PediRISE Resource Program

First Posted Date: 2024-02-28

Last Posted Date: 2024-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06283251

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy